Literature DB >> 8725160

Abnormal lipoproteins in the ANIT-treated rat: a transient and reversible animal model of intrahepatic cholestasis.

J W Chisholm1, P J Dolphin.   

Abstract

The alpha-naphthylisothiocyanate (ANIT)-treated rat was evaluated as a model for lipoprotein metabolism in cholestatic liver disease. Alterations in lipoprotein composition over a period of 120 h after ANIT treatment (100 mg/kg) were studied. Eighteen hours after treatment, plasma bilirubin and bile acid levels began to rise, together with significant increases in free cholesterol. C-18/16, C-18/18, and C-18/20 phospholipid molecular species. By 48 h, plasma lipid levels were maximal, free cholesterol was 935%, cholesteryl ester 294%, phospholipid 611%, and triacylglycerols 176% of controls, and the cholesteryl ester to free cholesterol ratio began to recover with a modest shift from cholesteryl esters containing C-20 fatty acids to those containing C-18 fatty acids. Lecithin: cholesterol acyltransferase activity was near normal, lipoprotein lipase activity was increased, and hepatic triacylglycerol lipase activity was decreased. Density gradient ultracentrifugation of rat plasma demonstrated a marked shift in lipoprotein density towards the low density lipoprotein range, with the increased lipid being associated with apolipoproteins A-I and E. The presence of large 300-400 A particles and the high surface to core lipid ratio in this density range was consistent with the presence of lipoprotein-X-like vesicles. Apolipoprotein B-48 accumulation was observed in the high density fractions (d15 > 1.063 g/ml) suggesting that these rats have impaired lipoprotein remnant removal. All of these increased levels returned to near normal by 120 h. This study demonstrates that ANIT-treatment induces a transient, fully reversible, non-surgical intrahepatic cholestasis that results in many of the plasma lipoprotein abnormalities associated with human hepatic cholestasis and the bile duct-ligated rat.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725160

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse.

Authors:  R P Elferink; R Ottenhoff; J van Marle; C M Frijters; A J Smith; A K Groen
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

2.  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

Authors:  Yaping Liu; Jane Binz; Mary Jo Numerick; Steve Dennis; Guizhen Luo; Bhasha Desai; Kathleen I MacKenzie; Traci A Mansfield; Steven A Kliewer; Bryan Goodwin; Stacey A Jones
Journal:  J Clin Invest       Date:  2003-11-17       Impact factor: 14.808

3.  Predicting Target Genes of San-Huang-Chai-Zhu Formula in Treating ANIT-Induced Acute Intrahepatic Cholestasis Rat Model via Bioinformatics Analysis Combined with Experimental Validation.

Authors:  Jiaming Yao; Junbin Yan; Jinting Wu; Jianshun Yu; Beihui He; Xi Chen; Zhiyun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-01       Impact factor: 2.629

4.  Protective Effect of Brazilian Propolis against Liver Damage with Cholestasis in Rats Treated with α-Naphthylisothiocyanate.

Authors:  Tadashi Nakamura; Yoshiji Ohta; Koji Ohashi; Kumiko Ikeno; Rie Watanabe; Kenji Tokunaga; Nobuhiro Harada
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

5.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.